A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Academic Article uri icon

Overview

abstract

  • BACKGROUND: The epidermal growth factor receptor (EGFR) is part of the ErbB family of receptor tyrosine kinases and is known to be variably expressed in breast cancers. Cetuximab is a humanized monoclonal antibody directed against the EGFR that works by blocking the downstream signaling function of this protein and thereby interfering with cancer cell proliferation. Preclinical studies have indicated a synergistic effect for the combination of anti-EGFR therapy plus paclitaxel in breast cancer models. PATIENTS AND METHODS: Hence, we conducted a dose-escalation phase I trial using cetuximab/paclitaxel in patients with metastatic breast cancer to evaluate the feasibility of this combination. Patients with EGFR-positive metastatic breast cancer treated with

publication date

  • August 1, 2006

Research

keywords

  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms

Identity

Scopus Document Identifier

  • 33749011681

Digital Object Identifier (DOI)

  • 10.3816/CBC.2006.n.040

PubMed ID

  • 16942645

Additional Document Info

volume

  • 7

issue

  • 3